The effect of incident antidiabetic regimens on lipid profiles in veterans with type 2 diabetes: A retrospective cohort

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 1, 2011, Pages 36-44

  Roumie, Christianne L ^a,b   Huizinga, Mary Margaret ^c   Liu, Xulei ^a,b   Greevy, Robert A ^a,b   Grijalva, Carlos G ^b   Murff, Harvey J ^a,b   Hung, Adriana M ^a,b   Griffin, Marie R ^a,b  

^a Clinical Research Center of Excellence (CRCoE)   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Comparative effectiveness; Diabetes; Lipids

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; LIPIDS; MALE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VETERANS;

EID: 78650364784     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2029     Document Type: Article

References (22)

1. Garber AJ, Karlsson FO. Treatment of dyslipidemia in diabetes. Endocrinol Metab Clin North Am 2001; 30: 999-1010.
2. Ginsberg HN, Tuck C. Diabetes and dyslipidemia. Heart Fail Monit 2001; 2: 14-20.
3. Howard BV, Howard WJ. Dyslipidemia in non-insulin-dependent diabetes mellitus. Endocr Rev 1994; 15: 263-274.
4. Laakso M. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. J Diabet Complications 1997; 11: 137-141.
5. Stern MP, Haffner SM. Dyslipidemia in type II diabetes. Implications for therapeutic intervention. Diabetes Care 1991; 14: 1144-1159.
6. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133-156.
7. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
8. International Classification of Diseases, Ninth Revision, Clinical Modification. Public Health Service, US Dept of Health and Human Services: Washington, DC, 1988.
9. Hynes DM, Koelling K, Stroupe K, et al. Veterans' access to and use of medicare and veterans affairs health care. Med Care 2007; 45: 214-223.
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-920.
11. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; CD006627.
12. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17.
13. Lin D, Wei L. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-1078.
14. Huizinga MM, Roumie CL, Elasy TA, et al. Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005. Diabetes Care 2007; 30: e85.
15. Executive summary: standards of medical care in diabetes-2009. Diabetes Care 2009; 32 (Suppl 1): S6-S12.
16. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32 (Suppl 1): S13-S61.
17. Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005; 70: 263-269.
18. Huizinga MM, Roumie CL, Greevy RA. Glycemic and weight changes after persistent use of incident oral diabetes therapy; a veterans administration retrospective cohort study. Pharmacoepidemiology and Drug Safety; in press.
19. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
20. Wright RA, Flapan AD, McMurray J, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
21. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44: 471-477.
22. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. The National Academies Press: Washington, DC, 2009.